Epidarex Portfolio News

08 Dec

45

Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)

In All, Portfolio

LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, will present an update on its Phase 1b PHAROAH trial at the 12th Annual Scientific Assembly…

07 Dec

64

Epidarex Capital Portfolio Company Harpoon Medical Acquired by Edwards Lifesciences

In All, Portfolio

Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today announced that its portfolio company, Harpoon Medical, Inc. (“Harpoon”), a pioneer in beating-heart repair for degenerative mitral regurgitation (DMR), has…

14 Nov

77

Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes Initial Public Offering

In All, Portfolio

Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”) of its portfolio company Apellis Pharmaceuticals, Inc. (“Apellis”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds…

13 Nov

49

Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

In All, Portfolio

Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering of 10,714,000 shares of common…

08 Nov

29

Apellis Pharmaceuticals Announces Pricing of Initial Public Offering

In All, Portfolio

Crestwood, Kentucky, Nov. 08, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its initial public offering of 10,714,000 shares of…

06 Nov

33

New Study: Innovative Heart Device is Safe and Effective

In All, Portfolio

Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery. The Harpoon Mitral Valve…

02 Nov

32

Topas Therapeutics Extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

In All, Portfolio

Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas ́ Board of Directors Hamburg, 2 November 2017,  – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based…

26 Oct

27

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

In All, Portfolio

Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas’ clinical development and regulatory affairs Hamburg, 26 October 2017,  – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…